Showing 7721-7730 of 8649 results for "".
- A 25-Year-Old Man Becomes First in the U.S. to Contract Coronavirus Twicehttps://modernod.com/news/a-25-year-old-man-becomes-first-in-the-u-s-to-contract-coronavirus-twice/2478412/A 25-year-old man in the U.S. state of Nevada has contracted the coronavirus on two separate occasions, a study in the Lancet Infectious Diseases journal showed
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho
- Orbis International Releases First Guide for Creating Simulation Training Programs for Eye Care Professionalshttps://modernod.com/news/orbis-international-releases-first-guide-for-creating-simulation-training-programs-for-eye-care-professionals/2478395/On World Sight Day, Orbis International announced the release of its Simulation Center Manual, a new practical implementation guide for training hospitals and teaching institutions looki
- Oertli Releases Two Trocar Based Chandelier Solutionshttps://modernod.com/news/oertli-releases-two-trocar-based-chandelier-solutions/2478389/Oertli announced the release of two trocar based chandelier solutions. Using chandelier illumination provides a true bimanual manipulation during vitreoretinal surgery and also one-step access for an easy and quick connection. Chandelier illumination is beneficial for improving intraocular
- In Recognition of World Sight Day, Lighthouse Guild Receives Donation from Bausch Foundation to Support Computer Training for People with Vision Losshttps://modernod.com/news/in-recognition-of-world-sight-day-lighthouse-guild-receives-donation-from-bausch-foundation-to-support-computer-training-for-people-with-vision-loss/2478391/Lighthouse Guild has received a $10,000 gift from Bausch Foundation to purchase new computers to train people with vision loss for work, school and daily living. The computers will be used at Lighthouse Guild’s Assistive Technology Training Center in Manhattan. Assistive technology include
- FDA Releases EUA Guidelines That May Extend Review Time for COVID-19 Vaccineshttps://modernod.com/news/fda-releases-eua-guidelines-that-may-extend-review-time-for-covid-19-vaccines/2478381/The FDA on Tuesday published briefing documents related to an upcoming advisory committee (AdCom) meeting on COVID-19 vaccines, as well as guidance for industry, in which it outlines anticipated stricter criteria that need to be met in order to support an emergency-use authorization (EUA) request
- Zeiss Partners With Microsoft for Better Patient Care Through Data-Driven Health Carehttps://modernod.com/news/zeiss-partners-with-microsoft-for-better-patient-care-through-data-driven-health-care/2478383/Zeiss Group and Microsoft announced a multi-year strategic partnership to accelerate Zeiss’ transformation into a digital services provider that is embracing a cloud-first approach. By standardizing its equipment and processes on Microsoft Azure as its preferred cloud platform, Zeiss will b
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosahttps://modernod.com/news/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/2478365/Eyevensys announced that the FDA has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa (RP). Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with RP, as well as other degenerat
- Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 for Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-treats-first-patients-in-three-phase-3-studies-of-ksi-301-for-retinal-diseases/2478361/Kodiak Sciences announced that the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER, and BEACON studies, three pivotal phase 3 studies of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in treatment-naïve patients with diabetic macular edema (GLEAM